Surintip PiamsomboonAndrzej P. KudelkaWichai TermrungruanglertKoen Van BesienCreyhton L. EdwardsSamuel LifshitzDonald F. SchomerRichard ChamplinRosario P. ManteJohn J. KavanaghClaire F. VerschraegenMahidol UniversityUniversity of Texas MD Anderson Cancer CenterChulalongkorn UniversityPresbyterian Hospital of Dallas2018-07-042018-07-041997-12-17European Journal of Gynaecological Oncology. Vol.18, No.6 (1997), 453-456039229362-s2.0-9844255061https://repository.li.mahidol.ac.th/handle/20.500.14594/18010Gestational trophoblastic disease (GTD) metastatic to the brain has a very poor prognosis with a survival rate of less than 25%, especially for patients in whom brain metastases develop while on or after chemotherapy. Cure can be achieved by chemotherapy alone. The regimen of etoposide, methotrexate, actinomycin-D, vincristine, and cyclophosphamide has shown encouraging results and is considered to be standard first-line treatment for high risk patients. For patients in whom this regimen fails, a salvage chemotherapy regimen is used. The combination of ifosfamide, carboplatin, and etoposide (ICE) has synergistic activity in preclinical studies. This regimen has shown activity in metastatic breast cancer and non-small-cell lung cancer as well as platinum-resistant germ-cell tumors and metastatic GTD. This is the first report of a patient with a highly refractory GTD in whom brain metastasis developed while on chemotherapy, and whose brain metastasis went into remission with a low dose ICE regimen. Accordingly, ICE may be considered for patients with chemotherapy refractory GTD metastatic to the brain.Mahidol UniversityMedicineArticleSCOPUS